BeiGene, Ltd. (BGNE)
Pre-Market:
| Previous Close | 194.47 |
| Open | 199.10 |
| Bid | 155.68 x 800 |
| Ask | 267.86 x 1200 |
| Day's Range | 198.00 - 205.83 |
| 52 Week Range | 118.18 - 426.56 |
| Volume | |
| Avg. Volume | 305,691 |
| Market Cap | 21.485B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.17 |
| Earnings Date | Aug 07, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 315.21 |
- Business Wire
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
CAMBRIDGE, U.S. & BASEL, Switzerland & BEIJING, August 09, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable he
- Business Wire
BeiGene Reports Second Quarter 2022 Financial Results
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 04, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.
- Zacks
Why BeiGene (BGNE) Might Surprise This Earnings Season
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
